2Q5 Stock Overview
Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Renovaro Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$2.28 |
52 Week High | US$4.52 |
52 Week Low | US$0.49 |
Beta | 0.30 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | -19.15% |
5 Year Change | -56.88% |
Change since IPO | -61.42% |
Recent News & Updates
Recent updates
Shareholder Returns
2Q5 | DE Biotechs | DE Market | |
---|---|---|---|
7D | 0% | -0.2% | 0.5% |
1Y | n/a | -22.8% | 1.3% |
Return vs Industry: Insufficient data to determine how 2Q5 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 2Q5 performed against the German Market.
Price Volatility
2Q5 volatility | |
---|---|
2Q5 Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 5.0% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2Q5 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 2Q5's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 12 | Mark Dybul | renovarobio.com |
Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company’s product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells.
Renovaro Inc. Fundamentals Summary
2Q5 fundamental statistics | |
---|---|
Market cap | €264.29m |
Earnings (TTM) | -€38.50m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.9x
P/E RatioIs 2Q5 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2Q5 income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$41.23m |
Earnings | -US$41.23m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.29 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 16.5% |
How did 2Q5 perform over the long term?
See historical performance and comparison